tldrdailynews.com logo
Tag

Psychedelic Therapy

All articles tagged with #psychedelic therapy

One-Time Psilocybin Dose May Prompt Lasting Brain Changes
science25 days ago

One-Time Psilocybin Dose May Prompt Lasting Brain Changes

A small study found that a single 25 mg dose of psilocybin in 28 volunteers produced detectable brain structural changes a month later via diffusion tensor imaging, with reduced diffusion along certain front-to-middle brain tracts, possibly due to fiber pruning or growth of unmyelinated fibers. An immediate surge in brain entropy during the experience correlated with deeper psychological insights and improved wellbeing a month afterward. Findings are preliminary given the small sample size and the indirect nature of DTI measurements, but they contribute to understanding how psychedelics might support mental health.

via The Guardian|
#brain-entropy#brain-plasticity#diffusion-tensor-imaging
One Psilocybin Dose Triggers Lasting Brain Changes and Mood Boost
science25 days ago

One Psilocybin Dose Triggers Lasting Brain Changes and Mood Boost

A study of 28 psilocybin-naive adults finds a single 25 mg dose can reconfigure brain activity and boost psychological well-being for up to a month. Researchers tracked brain changes with EEG, DTI, and fMRI, and found that higher brain entropy during the trip, along with greater psychological insights the next day, correlated with longer-term wellbeing improvements. The trial included a placebo session (1 mg) before the full dose, and participants could often tell which session contained the drug, which modestly limits the findings. The results help explain how psychedelic experiences may contribute to therapy, though some scientists caution that brain entropy is not a definitive biomarker and call for more sensitive measures.

via ScienceAlert|
#brain-entropy#mental-health#neuroimaging
FDA Accelerates Development and Access to Psychedelic Mental Health Treatments After Executive Order
health1 month ago

FDA Accelerates Development and Access to Psychedelic Mental Health Treatments After Executive Order

Following a presidential executive order, the FDA announced actions to speed development and access to treatments for serious mental illness, including national priority vouchers for psilocybin in treatment-resistant depression and major depressive disorder and for PTSD treated with methylone, approval of an early-phase study of noribogaine hydrochloride for alcohol use disorder (the first U.S. trial of an ibogaine derivative), and imminent final guidance to shape serotonin-2A agonist trials—emphasizing rigorous science and safety, especially for veterans.

via fda.gov|
#clinical-trials#fda#health
Psilocybin reshapes brain rhythms and connectivity, predicting psychedelic intensity
neuroimaging2 months ago

Psilocybin reshapes brain rhythms and connectivity, predicting psychedelic intensity

An EEG study of 25 healthy volunteers shows psilocybin shifts the brain from a resting state to a dynamically engaged pattern by reducing slow theta/alpha power and increasing fast beta/gamma activity, with enhanced connectivity in the default mode network and parietal networks that correlates with the intensity of the psychedelic experience. Baseline fast-wave activity in frontal/emotional regions also predicted response to the drug. Using a double-blind, randomized crossover design (10–20 mg psilocybin vs placebo), researchers highlight potential biomarkers to guide psychedelic-assisted therapies, while noting limitations from the small, healthy-sample size and the need for clinical population studies and autonomic markers like heart-rate variability.

via PsyPost|
#brain-rhythms#default-mode-network#eeg
One Short DMT Dose Sparks Lasting Depression Relief in Phase IIa Trial
health3 months ago

One Short DMT Dose Sparks Lasting Depression Relief in Phase IIa Trial

A Phase IIa randomized trial found that a single 21.5 mg IV dose of DMT, producing a ~25-minute psychedelic experience, yielded rapid and durable antidepressant effects in adults with moderate-to-severe treatment-resistant depression—MADRS scores dropped more than placebo within one week and effects persisted up to six months for some participants; efficacy correlated with the intensity of the peak experience, and the brief session could be more cost-effective and easier to implement than longer psychedelic therapies, though larger trials are needed and use is restricted to controlled clinical settings with professional support.

via Neuroscience News|
#depression#dmt#health
Small DMT Trial Signals Potential Depression Treatment
health3 months ago

Small DMT Trial Signals Potential Depression Treatment

A small UK Phase IIa randomized, placebo-controlled trial found that a single dose of DMT with psychotherapy significantly reduced depressive symptoms for up to three months (some participants up to six); 47% reached remission at three months. DMT appeared safe and well tolerated, but the study's small size means larger, longer trials are needed before it could become a standard depression treatment.

via Gizmodo|
#depression#dmt#health
2025 Neuroscience Highlights: Key Discoveries and Future Predictions
science5 months ago

2025 Neuroscience Highlights: Key Discoveries and Future Predictions

In 2025, significant advancements in consciousness research included exploring the possibility of universal consciousness before the Big Bang, recognizing consciousness as more widespread and ancient across species, breakthroughs in psychedelic therapy and altered states, progress in competing theories of consciousness, and increased attention to near-death experiences and their psychological impact, marking a shift towards viewing consciousness as a tangible scientific frontier.

via The Debrief|
#consciousness#near-death-experiences#neuroscience
Single LSD Dose May Reduce Anxiety, Study Finds
health8 months ago

Single LSD Dose May Reduce Anxiety, Study Finds

A new study shows that a single high dose of LSD (MM120) can significantly reduce anxiety and depression in adults with generalized anxiety disorder, with effects lasting up to 12 weeks, though environmental factors may also influence outcomes. The research supports the potential of psychedelics as future psychiatric treatments, pending further studies and FDA approval.

via NPR|
#anxiety#gad#health
AbbVie Acquires Gilgamesh's Psychedelic Depression Therapy in $1.2B Deal
business9 months ago

AbbVie Acquires Gilgamesh's Psychedelic Depression Therapy in $1.2B Deal

AbbVie is acquiring Gilgamesh Pharmaceuticals' investigational drug bretisilocin, a promising psychedelic therapy in Phase 2 trials for major depressive disorder, aiming to expand its psychiatric treatment portfolio. The drug has shown significant antidepressant effects with a shorter psychoactive duration, and the deal includes up to $1.2 billion in potential payments. This move underscores AbbVie's commitment to innovative mental health treatments.

via AbbVie News Center|
#abbvie#bretisilocin#business